Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Liquidias global settlement with United Therapeutics resolves the companies pending litigation and allows continued YUTREPIA commercialization for PAH. Traders largely welcome the reduced legal uncertainty, while some remain cautious about the settlements financial cost and debate how much upside the resolution leaves.

Bank of Americas anti-money-laundering and sanctions compliance failures drew attention after regulators imposed a major penalty ahead of its quarterly results. Traders are split between dismissing the fine as manageable and viewing it as a reputational and near-term downside risk, with some also focused on the upcoming earnings report.

Cipher Digitals proposed zero-coupon convertible-note offering is driving a sharp selloff, with traders concerned about dilution, share exchanges, and the timing of the financing. Bulls argue the low-cost capital can fund Barber Lake and the companys AI data-center buildout, while the extent of dilution remains a concern as final terms are pending.

Investors are weighing Take-Twos upcoming Grand Theft Auto VI launch against recent share weakness. Many expect strong sales and future GTA Online monetization to support the stock, while others argue launch expectations are already priced in and point to uncertainty around online features, leaks, and execution.

JPMorgans third-quarter results missed expectations, with weaker fixed-income trading and a securities loss weighing on earnings, while stronger net interest income and other business lines partly offset the shortfall. Traders are divided over the stocks resilient price action despite the miss, weighing the weak headline against the banks underlying lending strength and outlook.

Ryan Cohens reported purchase of 844,130 GameStop shares is driving attention, with many traders viewing the insider buying as bullish and speculating about a short squeeze or share buyback. Others question whether the buying can sustain gains and point to potential dilution tied to warrants.

Fubos sharp, low-volume swings and recent selloff dominate discussion, with traders noting no clear new negative catalyst and debating whether thin trading is amplifying the decline. Bulls are focused on the new CEOs strategic plan and the next earnings report, while bears point to dilution risks, weak fundamentals, and the stocks prolonged downtrend.

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is the dominant focus, with traders debating whether the HOPE-3 extension data and company-presented robustness analyses strengthen the case for approval. Bulls see a path to approval, while skeptics point to the FDAs statistical concerns and possible CRL; the share-price decline has intensified that disagreement.

Applied Materials selloff is being tied to its Investor Day, where management offered no specific near-term wafer-fab equipment spending forecast, leaving traders uncertain about demand despite ambitious long-term targets. Some see the decline as an overreaction and a buying opportunity, while others argue expectations were already high and near-term growth visibility is lacking.

Nasdaqs planned expansion to nearly continuous, 23-hour weekday trading is a key discussion topic, alongside its broader push into tokenized equities and round-the-clock market infrastructure. Traders see potential for more access and exchange activity, while others question whether overnight trading will bring thinner liquidity and added volatility.